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Breast cancer 
screening
Nina Mingioni, MD FACP
Thomas Jefferson University Hospital
Learning Objectives
• Assess patients for risk of breast cancer
• Name common breast cancer screening modalities
• Discuss risks and benefits of breast cancer screening
• Recommend breast cancer screening for appropriate patients
What is the scope of the problem?
• Most common non-skin cancer in women
• Risk of breast cancer:
• Cumulative lifetime risk of invasive breast cancer is 12.8%
• 30yo: 10yr risk for developing breast cancer is 0.48% (1 in 208)
• 40yo: 10yr risk for developing breast cancer is 1.53% (1 in 65)
• 50yo: 10yr risk for developing breast cancer is 2.38% (1 in 42)
• 60yo: 10yr risk for developing breast cancer is 3.54% (1 in 28)
• 70yo: 10yr risk for developing breast cancer is 4.07% (1 in 25)
• Only 10% of breast cancers are associated with positive family history
https://www.cancer.gov/types/breast/risk-fact-sheet
U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017): U.S. Department of Health and Human Services, Centers for Disease Control 
and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, released in June 2020




average-risk women with 
no current or previous 
breast abnormalities





• Current physical exam finding
• Previous breast cancer or 
other breast anomaly (DCIS, 
LCIS, etc.)
• BRCA mutation
• Strong family history (>15% risk)
• Other high-risk factors 
(chest radiation, familial 
cancer syndromes, etc.)
Nattinger AB, Mitchell JL. Breast Cancer Screening and Prevention. Ann Intern Med. 2016;164(11):ITC81-ITC96.
Models Predicting Breast Cancer Risk
Breast Cancer Risk Assessment Tool
https://www.cancer.gov/bcrisktool/
Breast Cancer Surveillance Consortium Calculator
https://tools.bcsc-scc.org/bc5yearrisk/calculator.htm
What are the 
screening modalities?
• Clinical breast examination
• Digital mammography
• single view breast X-ray
• breast is significantly compressed between two plates
• creates a 2D image
• 3D mammography (breast tomosynthesis)
• tomosynthesis creates image of breast from multiple 
angles 
• 11 images over 7 seconds with computerized 3D 
reconstruction
• breast is not significantly squeezed
• Breast MRI
https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/mammogram-basics.html
Digital Mammo vs Digital Breast Tomosynthesis
• DBT exposes to twice as much radiation as DM
• Higher cost; longer reading time
• Observational studies only:
• No measure of breast CA mortality, cancer stage, or quality of life
• Increased breast CA detection as compared to DM
• No differences in interval cancer detection rate, recall rate, or FP
• Specific recommendations NOT to use DBT by Canadian, European 
guidelines
Schünemann HJ, Lerda D, Quinn C, et al. Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. Ann Intern Med. 2020;172(1):46-56.
Conant EF, Barlow WE, Herschorn SD, et al. Association of Digital Breast Tomosynthesis vs Digital Mammography With Cancer Detection and Recall Rates by Age and Breast Density. JAMA Oncol. 
2019;5(5):635-642.




• 15-20% reduction in breast cancer mortality in 
all age groups (metanalyses data)
• benefit varies by age group
• no reduction in all-cause mortality in any 
age group
• mammo screening is protective against 
advanced breast cancer >50yo




women for 10 
years
Nattinger AB, Mitchell JL. Breast Cancer Screening and Prevention. Ann Intern Med. 2016;164(11):ITC81-ITC96.
Number needed to screen 
to prevent 1 breast cancer death
Age group 40-49 50-59 60-69 70-79 80-84
NNS 
(annual)
746 351 233 377 1316
NNS 
(biannual)
1034 455 303 1339 1339
Hendrick RE, Helvie MA. Mammography screening: a new estimate of number needed to screen to prevent one 





• Anxiety/psychologic distress for 
up to 2 years!
• Need for more imaging and 
biopsy
• After 10 years of annual 
screening, chance for needing 
more imaging is 50-60%,  and 
40% with biannual screening 
• After 10 years of annual 
screening chance of unnecessary 
biopsy 7-10%. 
Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years 




• Overdiagnosis =early diagnosis of 
cancer that would never have 
progressed to clinical importance in 
absence of screening (mostly DCIS, but 
probably even some more aggressive 
cancers)
• Probably 10-20% of all cancers 
diagnosed
• Harms of treatment w/o benefit
• Once diagnosed, no way to 






• 0.4-1.2 deaths per 10,000 women screened 
over lifetime 
Siu AL, U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(4):279-296.
Guideline, Year Clinical Breast Exam Age to Start Screening Mammography or Discuss/Shared Decision Making Age to Stop Screening Screening Interval
ACOG, 2017 Recommend doing CBE
40 y (discuss; offer if chosen by SDM)
50 y (start screening if not previously 
started)
≥75 y Annual or biennial
ACR, 2017 No recommendation 40 y (start screening) None Annual
ACS, 2015 Recommend against CBE 40–44 y (discuss; offer if chosen by SDM) 45 y (start screening) Life expectancy <10 y
Annual for age 45–54 y 
Biennial for age ≥55 y
CTFPHC, 2018 Recommend against CBE 50 y (start screening) No recommendation* Every 2–3 y
ECIBC, 2020 (not addressed) 45 y (start screening) 75yo
Every 2–3 y for 45-49 y
Biennial for age 50-69 y
Every 3 y for 70-74 y
USPSTF, 2016 No recommendation† 40–49 y (discuss; offer if chosen by SDM) 50 y (start screening) 75 y Biennial
WHO, 2014 Recommend doing CBE (low-resource settings only) 50 y (start screening) 75 y Biennial
Schünemann HJ, Lerda D, Quinn C, et al. Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. Ann Intern Med. 2020;172(1):46-56.
Bottom Line(s)
• Frequency (annual vs biannual) and starting age (40 vs 50) is based 
on shared decision making
• Start screening average risk women at 50yo
• Screen annually for higher risk women
• Extremely dense breasts
• Family history in 1° or 2° relative
• Screen with MRI only for very high-risk women
Nattinger AB, Mitchell JL. Breast Cancer Screening and Prevention. Ann Intern Med. 2016;164(11):ITC81-ITC96.
https://bsd.weill.cornell.edu/#/

Don’t forget to 
talk to your 
patients about 
mammograms!
Hsiang EY, Mehta SJ, Small DS, et al. Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening. JAMA Netw
Open. 2019;2(5):e193403.
